246 related articles for article (PubMed ID: 19281081)
1. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease.
Hooper C; Calvert J
Int J Chron Obstruct Pulmon Dis; 2008; 3(4):659-69. PubMed ID: 19281081
[TBL] [Abstract][Full Text] [Related]
2. Effect of CArbocisteine in Prevention of exaceRbation of chronic obstructive pulmonary disease (CAPRI study): An observational study.
Esposito A; Valentino MR; Bruzzese D; Bocchino M; Ponticiello A; Stanziola A; Sanduzzi A
Pulm Pharmacol Ther; 2016 Apr; 37():85-8. PubMed ID: 26970503
[TBL] [Abstract][Full Text] [Related]
3. Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis.
Zeng Z; Yang D; Huang X; Xiao Z
Int J Chron Obstruct Pulmon Dis; 2017; 12():2277-2283. PubMed ID: 28814855
[TBL] [Abstract][Full Text] [Related]
4. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study.
Zheng JP; Kang J; Huang SG; Chen P; Yao WZ; Yang L; Bai CX; Wang CZ; Wang C; Chen BY; Shi Y; Liu CT; Chen P; Li Q; Wang ZS; Huang YJ; Luo ZY; Chen FP; Yuan JZ; Yuan BT; Qian HP; Zhi RC; Zhong NS
Lancet; 2008 Jun; 371(9629):2013-8. PubMed ID: 18555912
[TBL] [Abstract][Full Text] [Related]
5. Maculopapular rash to S-carboxymethylcysteine-lysine (carbocisteine).
Gomez Torrijos E; Gratacós Gómez AR; Extremera Ortega AM; Gonzalez Jimenez OM; Romo JBJ; Cañas AP; Rodriguez RG
Contact Dermatitis; 2020 Oct; 83(4):313-314. PubMed ID: 32356398
[No Abstract] [Full Text] [Related]
6. Use of mucolytics in COPD: A Delphi consensus study.
Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y
Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537
[TBL] [Abstract][Full Text] [Related]
7. Carbocisteine for acute exacerbations of COPD.
Waller P; Suissa S
Lancet; 2008 Nov; 372(9650):1630; author reply 1631-2. PubMed ID: 18994655
[No Abstract] [Full Text] [Related]
8. Carbocisteine for acute exacerbations of COPD.
Mohapatra PR; Aggarwal D
Lancet; 2008 Nov; 372(9650):1630-1; author reply 1631-2. PubMed ID: 18994656
[No Abstract] [Full Text] [Related]
9. The effect and mechanism of action of carbocysteine on airway bacterial load in rats chronically exposed to cigarette smoke.
Sun L; Tang L; Xu Y; Wang S; Li Y; Kang J
Respirology; 2010 Oct; 15(7):1064-71. PubMed ID: 20807377
[TBL] [Abstract][Full Text] [Related]
10. Carbocisteine can scavenge reactive oxygen species in vitro.
Nogawa H; Ishibashi Y; Ogawa A; Masuda K; Tsubuki T; Kameda T; Matsuzawa S
Respirology; 2009 Jan; 14(1):53-9. PubMed ID: 19144049
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
[TBL] [Abstract][Full Text] [Related]
12. A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial.
Bradley JM; Anand R; O'Neill B; Ferguson K; Clarke M; Carroll M; Chalmers J; De Soyza A; Duckers J; Hill AT; Loebinger MR; Copeland F; Gardner E; Campbell C; Agus A; McGuire A; Boyle R; McKinney F; Dickson N; McAuley DF; Elborn S;
Trials; 2019 Dec; 20(1):747. PubMed ID: 31856887
[TBL] [Abstract][Full Text] [Related]
13. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases.
Macciò A; Madeddu C; Panzone F; Mantovani G
Expert Opin Pharmacother; 2009 Mar; 10(4):693-703. PubMed ID: 19239402
[TBL] [Abstract][Full Text] [Related]
14. Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease.
Tatsumi K; Fukuchi Y;
J Am Geriatr Soc; 2007 Nov; 55(11):1884-6. PubMed ID: 17979906
[No Abstract] [Full Text] [Related]
15. Efficacy of carbocisteine in the treatment of chronic obstructive pulmonary disease and impact on the quality of life.
Alibašić E; Skopljak A; Čengić A; Krstović G; Trifunović N; Čatić T; Kapo B; Mehić M; Hadžimuratović A
Med Glas (Zenica); 2017 Aug; 14(2):182-188. PubMed ID: 28786969
[TBL] [Abstract][Full Text] [Related]
16. A mucoactive drug carbocisteine ameliorates steroid resistance in rat COPD model.
Song Y; Yu P; Lu JJ; Lu HZ; Zhu L; Yu ZH; Chen HZ; Cui YY
Pulm Pharmacol Ther; 2016 Aug; 39():38-47. PubMed ID: 27328977
[TBL] [Abstract][Full Text] [Related]
17. [Cell oxidative processes and antioxidant mucoactive drugs].
González-Mangado N; Morera Prat J
Arch Bronconeumol; 2001 Nov; 37(10):407-10. PubMed ID: 11734120
[No Abstract] [Full Text] [Related]
18. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys).
Carpagnano GE; Resta O; Foschino-Barbaro MP; Spanevello A; Stefano A; Di Gioia G; Serviddio G; Gramiccioni E
Eur J Pharmacol; 2004 Nov; 505(1-3):169-75. PubMed ID: 15556150
[TBL] [Abstract][Full Text] [Related]
19. A prospective study of the effects of carbocysteine lysine salt on frequency of exacerbations in COPD patients treated with or without inhaled steroids.
Paone G; Lanata L; Saibene F; Toti S; Palermo P; Graziani C; Flore MC; Ramaccia M; Puglisi G
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6727-6735. PubMed ID: 31378916
[TBL] [Abstract][Full Text] [Related]
20. Carbocisteine: frequent cutaneous adverse effects.
Prescrire Int; 2007 Feb; 16(87):17. PubMed ID: 17326276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
